Eyenovia Inc. News Releases http://ir.eyenoviabio.com/ Eyenovia Inc. News Releases en Eyenovia Reports First Quarter 2019 Financial Results http://ir.eyenoviabio.com/news-releases/news-release-details/eyenovia-reports-first-quarter-2019-financial-results NEW YORK , May 14, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the first quarter ended Tue, 14 May 2019 06:30:00 -0400 Eyenovia Inc. News Releases 7261 Eyenovia Announces Presentation of Successful Phase 3 Studies at the ASCRS-ASOA Annual Meeting http://ir.eyenoviabio.com/news-releases/news-release-details/eyenovia-announces-presentation-successful-phase-3-studies-ascrs Presented Positive Results from Two Phase 3 MicroStat (phenylephrine 2.5% / tropicamide 1% fixed combination ophthalmic solution) Trials NEW YORK , May 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose Mon, 06 May 2019 08:30:00 -0400 Eyenovia Inc. News Releases 7246 Eyenovia Announces Conference Call and Webcast for First Quarter 2019 Financial Results http://ir.eyenoviabio.com/news-releases/news-release-details/eyenovia-announces-conference-call-and-webcast-first-quarter-0 NEW YORK , May 01, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company will release financial results Wed, 01 May 2019 08:30:00 -0400 Eyenovia Inc. News Releases 7236 Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results http://ir.eyenoviabio.com/news-releases/news-release-details/eyenovia-reports-fourth-quarter-and-full-year-2018-financial NEW YORK , March 27, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the fourth quarter and Wed, 27 Mar 2019 06:30:00 -0400 Eyenovia Inc. News Releases 7191 Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results http://ir.eyenoviabio.com/news-releases/news-release-details/eyenovia-announces-conference-call-and-webcast-fourth-quarter-0 NEW YORK , March 13, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company will release financial results Wed, 13 Mar 2019 08:30:00 -0400 Eyenovia Inc. News Releases 7181 Eyenovia to Participate in Two Upcoming Investor Conferences http://ir.eyenoviabio.com/news-releases/news-release-details/eyenovia-participate-two-upcoming-investor-conferences NEW YORK , March 04, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that members of management will be participating Mon, 04 Mar 2019 08:30:00 -0500 Eyenovia Inc. News Releases 7176 Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis http://ir.eyenoviabio.com/news-releases/news-release-details/eyenovia-announces-confirmatory-results-second-microstat-phase MIST-2 study meets primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, good tolerability in confirmatory MIST-2 Study NEW YORK , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company Mon, 25 Feb 2019 08:30:00 -0500 Eyenovia Inc. News Releases 7151 Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering http://ir.eyenoviabio.com/news-releases/news-release-details/eyenovia-confirms-expanded-microprost-phase-iii-indication Expanded, more efficient development aimed at maximizing MicroProst's program value NEW YORK , Feb. 13, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print Wed, 13 Feb 2019 08:30:00 -0500 Eyenovia Inc. News Releases 7136 Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia http://ir.eyenoviabio.com/news-releases/news-release-details/eyenovia-announces-fda-acceptance-ind-application-micropine On track to initiate Phase III trial in H1 2019 NEW YORK , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced Wed, 06 Feb 2019 08:30:00 -0500 Eyenovia Inc. News Releases 7116 Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis http://ir.eyenoviabio.com/news-releases/news-release-details/eyenovia-announces-positive-results-microstat-mist-1-phase-iii MIST-1 study met primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, high tolerability; Study further validates OpteJet™ platform delivery technology Company to host conference call at 8:30 AM ET on January 30, 2019 NEW YORK , Jan. Wed, 30 Jan 2019 07:00:38 -0500 Eyenovia Inc. News Releases 7096